260 related articles for article (PubMed ID: 22898604)
1. Autophagic degradation of the BCR-ABL oncoprotein and generation of antileukemic responses by arsenic trioxide.
Goussetis DJ; Gounaris E; Wu EJ; Vakana E; Sharma B; Bogyo M; Altman JK; Platanias LC
Blood; 2012 Oct; 120(17):3555-62. PubMed ID: 22898604
[TBL] [Abstract][Full Text] [Related]
2. BCR-ABL/p62/SQSTM1: a cannibal embrace.
Auberger P
Blood; 2012 Oct; 120(17):3389-90. PubMed ID: 23100300
[TBL] [Abstract][Full Text] [Related]
3. BCR-ABL1-induced leukemogenesis and autophagic targeting by arsenic trioxide.
Goussetis DJ; Gounaris E; Platanias LC
Autophagy; 2013 Jan; 9(1):93-4. PubMed ID: 23051894
[TBL] [Abstract][Full Text] [Related]
4. Activation of mammalian target of rapamycin and the p70 S6 kinase by arsenic trioxide in BCR-ABL-expressing cells.
Yoon P; Giafis N; Smith J; Mears H; Katsoulidis E; Sassano A; Altman J; Redig AJ; Tallman MS; Platanias LC
Mol Cancer Ther; 2006 Nov; 5(11):2815-23. PubMed ID: 17121928
[TBL] [Abstract][Full Text] [Related]
5. In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia.
La Rosée P; Johnson K; O'Dwyer ME; Druker BJ
Exp Hematol; 2002 Jul; 30(7):729-37. PubMed ID: 12135670
[TBL] [Abstract][Full Text] [Related]
6. Autophagy is a critical mechanism for the induction of the antileukemic effects of arsenic trioxide.
Goussetis DJ; Altman JK; Glaser H; McNeer JL; Tallman MS; Platanias LC
J Biol Chem; 2010 Sep; 285(39):29989-97. PubMed ID: 20656687
[TBL] [Abstract][Full Text] [Related]
7. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.
Zeng X; Zhao H; Li Y; Fan J; Sun Y; Wang S; Wang Z; Song P; Ju D
Autophagy; 2015; 11(2):355-72. PubMed ID: 25701353
[TBL] [Abstract][Full Text] [Related]
8. Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L).
Perkins C; Kim CN; Fang G; Bhalla KN
Blood; 2000 Feb; 95(3):1014-22. PubMed ID: 10648417
[TBL] [Abstract][Full Text] [Related]
9. Resveratrol enhances the suppressive effects of arsenic trioxide on primitive leukemic progenitors.
Wu EJ; Goussetis DJ; Beauchamp E; Kosciuczuk EM; Altman JK; Eklund EA; Platanias LC
Cancer Biol Ther; 2014 Apr; 15(4):473-8. PubMed ID: 24496081
[TBL] [Abstract][Full Text] [Related]
10. Arsenic sulfide nanoformulation induces erythroid differentiation in chronic myeloid leukemia cells through degradation of BCR-ABL.
Wang T; Wen T; Li H; Han B; Hao S; Wang C; Ma Q; Meng J; Liu J; Xu H
Int J Nanomedicine; 2019; 14():5581-5594. PubMed ID: 31413564
[TBL] [Abstract][Full Text] [Related]
11. VEGF depletion enhances bcr-abl-specific sensitivity of arsenic trioxide in chronic myelogenous leukemia.
Luo X; Feng M; Zhu X; Li Y; Fei J; Zhang Y
Hematology; 2013 Nov; 18(6):334-40. PubMed ID: 24129092
[TBL] [Abstract][Full Text] [Related]
12. AMP-activated protein kinase activation primes cytoplasmic translocation and autophagic degradation of the BCR-ABL protein in CML cells.
Koyama D; Kikuchi J; Kuroda Y; Ohta M; Furukawa Y
Cancer Sci; 2021 Jan; 112(1):194-204. PubMed ID: 33070465
[TBL] [Abstract][Full Text] [Related]
13. Cathepsin B release after imatinib-mediated lysosomal membrane permeabilization triggers BCR-ABL cleavage and elimination of chronic myelogenous leukemia cells.
Puissant A; Colosetti P; Robert G; Cassuto JP; Raynaud S; Auberger P
Leukemia; 2010 Jan; 24(1):115-24. PubMed ID: 19924144
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of small GTPase RalA regulates growth and arsenic-induced apoptosis in chronic myeloid leukemia (CML) cells.
Zhu X; Li Y; Luo X; Fei J
Cell Signal; 2012 Jun; 24(6):1134-40. PubMed ID: 22330069
[TBL] [Abstract][Full Text] [Related]
15. Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells.
Carayol N; Vakana E; Sassano A; Kaur S; Goussetis DJ; Glaser H; Druker BJ; Donato NJ; Altman JK; Barr S; Platanias LC
Proc Natl Acad Sci U S A; 2010 Jul; 107(28):12469-74. PubMed ID: 20616057
[TBL] [Abstract][Full Text] [Related]
16. Anti-cancer fatty-acid derivative induces autophagic cell death through modulation of PKM isoform expression profile mediated by bcr-abl in chronic myeloid leukemia.
Shinohara H; Taniguchi K; Kumazaki M; Yamada N; Ito Y; Otsuki Y; Uno B; Hayakawa F; Minami Y; Naoe T; Akao Y
Cancer Lett; 2015 Apr; 360(1):28-38. PubMed ID: 25644089
[TBL] [Abstract][Full Text] [Related]
17. Hsp90 inhibitor, BIIB021, induces apoptosis and autophagy by regulating mTOR-Ulk1 pathway in imatinib-sensitive and -resistant chronic myeloid leukemia cells.
He W; Ye X; Huang X; Lel W; You L; Wang L; Chen X; Qian W
Int J Oncol; 2016 Apr; 48(4):1710-20. PubMed ID: 26892093
[TBL] [Abstract][Full Text] [Related]
18. EPS8 regulates proliferation, apoptosis and chemosensitivity in BCR-ABL positive cells via the BCR-ABL/PI3K/AKT/mTOR pathway.
Huang R; Liu H; Chen Y; He Y; Kang Q; Tu S; He Y; Zhou X; Wang L; Yang J; Wu A; Li Y
Oncol Rep; 2018 Jan; 39(1):119-128. PubMed ID: 29192326
[TBL] [Abstract][Full Text] [Related]
19. Caveolin-1 contributes to realgar nanoparticle therapy in human chronic myelogenous leukemia K562 cells.
Shi D; Liu Y; Xi R; Zou W; Wu L; Zhang Z; Liu Z; Qu C; Xu B; Wang X
Int J Nanomedicine; 2016; 11():5823-5835. PubMed ID: 27853367
[TBL] [Abstract][Full Text] [Related]
20. Multifaceted approach to the treatment of bcr-abl-positive leukemias.
O'Dwyer M
Oncologist; 2002; 7 Suppl 1():30-8. PubMed ID: 11961207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
